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Summary
The lymphotoxin axis is important for themaintenance
of several specialized lymphoid microenvironments in
secondary lymphoid tissue. Lymphoid-tissue archi-
tecture is highly plastic and requires continual homeo-
static signaling to maintain its basal functional state.
The cellularity of lymph nodes in adult mice was re-
duced by systemic blockade of lymphotoxin-b recep-
tor (LTbR) signaling with a soluble decoy receptor
both in resting and reactive settings. This reduction
in cellularity resulted from greatly impaired lympho-
cyte entry into lymph nodes due to decreased levels
of peripheral lymph node addressin (PNAd) and MAd-
CAM on high endothelial venules (HEV). LTbR signal-
ing was required to maintain normal levels of RNA ex-
pression of MAdCAM, and also of PNAd by regulating
the expression of key enzymes and scaffold proteins
required for its assembly. Thus, the homeostaticmain-
tenance of functional HEV status in adult mice relies
largely on LTbR signaling.
Introduction
Trafficking of lymphocytes into lymph nodes (LN) starts
with adherence to addressins on the luminal surfaces of
high endothelial venules (HEV) (Miyasaka and Tanaka,
2004; von Andrian and Mempel, 2003). Chemokines
present on the endothelial surface, e.g., CCL21 and
CXCL12, bind to receptors on lymphocytes, resulting
in integrin activation and enhanced adhesion of the lym-
phocyte. Finally, the lymphocytes transmigrate through
the vessel wall into the interstitial space. This multistep
process on HEVs constitutes the major gateway into
the LN for naive lymphocytes. Cells that exit the drain-
ing-tissue bed can also enter the LN via the afferent lym-
phatics, specifically effector/memory lymphocytes and
antigen bearing presenting cells. Low-molecular-weight
antigen and chemokines gain access to the conduit sys-
tem where antigen can be sampled by dendritic cells,
whereas larger components entering with the lymph
are restricted to the subcapsular and medullary spaces
*Correspondence: jeff.browning@biogenidec.com(Sixt et al., 2005). The ability to compartmentalize the LN
to optimize encounters between antigen-laden antigen-
presenting cells and T and B cells is critical for a fast and
sensitive response to antigen. The ability of the HEV to
selectively facilitate the entrance of naive lymphocyte
populations is essential to make this process highly
efficient.
The HEV, a specialized vascular ‘‘high’’ endothelium
found in LN and Peyer’s patches (PP), is unique in its ca-
pacity to efficiently promote adherence of naive lympho-
cytes. Endothelial cells of HEV synthesize and display li-
gands for L-selectin; these ligands are collectively called
peripheral lymph node addressins (PNAd), a class of
O-linked sialomucins (Lowe, 2002). The signals that in-
struct endothelial cells to acquire the ‘‘high endothelial’’
phenotype are unknown. The HEV structure remains
plastic in the adult, as was demonstrated by ligation of
the afferent lymphatics, which caused HEV to revert to
an endothelial surface lacking PNAd addressins (Hen-
driks et al., 1987; Kraal and Mebius, 1997; Mebius et al.,
1991). Thus, continual signaling is required to maintain
HEV endothelium.
The coordinated activities of specific biosynthetic en-
zymes are necessary to complete the posttranslational
modifications resulting in functional L-selectin binding
domains. Specifically, the GlcNac 6-O-sulphotrans-
ferases—i.e., GlcNAc6ST-1 (also called GST-2, CHST2)
and GlcNAc6ST-2 (also called LSST, GST-3, CHST4,
and HEC-GlcNac6ST)—the fucosyltransferases IV and
VII (FucT IV and VII), and some core glycosyl transferases
are critical components (Lowe, 2002; Miyasaka and Ta-
naka, 2004; von Andrian and Mempel, 2003). The PNAd
glycan is assembled, predominantly on GlyCAM, CD34,
podocalyxin, and MAdCAM scaffold proteins (Miyasaka
and Tanaka, 2004). Because ligation of the afferent lym-
phatics led to loss of PNAd as well as GlyCAM expres-
sion, it is reasonable to postulate the existence of a highly
coordinated program for HEV differentiation (Mebius
et al., 1993; Mebius et al., 1991; Swarte et al., 1998).
The cell-surface lymphotoxin-a/b (LTa/b)/lympho-
toxin-b receptor (LTbR) system is required to maintain
several aspects of lymphoid microenvironments (Gom-
merman and Browning, 2003; Ware, 2005). We had re-
ported that blocking LTbR signaling in mice decreased
cellularity in PP (Dohi et al., 2001). On the basis of this
and other observations made in reactive LN of immu-
nized mice, we investigated the role of the LT system
in LN trafficking. Here, we show that the cellularity of
LN is under LT control both in resting LN and in the drain-
ing inguinal LN in the collagen-induced arthritis (CIA)
model following immunization with type II collagen/
CFA. We reasoned that the markedly decreased LN
cellularity following LTbR blockade might involve
decreased cell entry rates, increased egress rates, or
reduced chemokine levels that were incapable of
sustaining the normal compartment size. Others
showed that in experimentally induced tertiary lymphoid
organs, HEV status was under LT control (Drayton et al.,
2003; Luther et al., 2000). When we examined the entry
mechanisms in normal LN, we found that constitutive
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540Figure 1. Loss of LTbR Signaling Results in
Decreased LN Cellularity in Naive and Reac-
tive LN
(A) Total LN and spleen cell counts from naive
Balb/c mice treated for 28 days with either
control IgG (open circles) or LTbR-Ig (solid
circles); iLN, aLN, cLN, and mLN refer to in-
guinal, axillary, cervical, and mesenteric LN,
respectively.
(B) Time course of the change in the cellular-
ity of reactive, draining iLN and nondraining
aLN from DBA-1 mice immunized with colla-
gen II in CFA on day 0. Mice were treated
with control Ig or LTbR-Ig (100 mg) or TNFR-
Ig (200 mg) weekly starting on day 29.
Data in (A) and (B) represent the mean and SD
from cell counts on pooled LN pairs from each
of five mice; all comparisons in (A) and those
with asterisks in (B) were significant with p <
0.05 relative to control-Ig-treated mice.LTbR activation regulates in the normal adult mouse
a multifaceted program of HEV differentiation required
for lymphocyte trafficking.
Results
Inhibition of the LT System Reduces Cell Numbers
in Peripheral Lymph Nodes
We treated Balb/c mice for 28 days with LTbR-Ig to de-
termine the effects on LN cellularity and found that
LTbR-Ig-treated naive mice had reduced cell numbers
in all LN groups, including both mucosal and peripheral
LN (Figure 1A). This observation was replicated in stud-
ies of the expansion that occurs upon immunization in
reactive LN. LTbR-Ig treatment for 9 days prior to immu-
nization of DBA-1 mice with collagen II in CFA effectively
inhibited the expansion of the draining inguinal LN (iLN)
(Figure 1B). In this setting, the iLN expand to contain
over 10 million cells/LN that can be sustained for at least
6 weeks with secondary immunization (data not shown).
This preimmunization treatment (i.e., 2 weeks) com-
pletely blocked development of CIA disease. LTbR-Ig
also inhibited the CIA disease process when adminis-
tered either on the day of immunization or with fully es-
tablished disease (Fava et al., 2003). If LTbR-Ig treat-
ment was begun concomitantly with immunization, the
cellularity of the draining iLN was similarly reduced at
d28; however, if LTbR-Ig treatment was initiated 2 weeks
after the immunization, the cellularity was only partially
reduced (data not shown). These experiments indicated
that the effects of LTbR-Ig treatment require about 1–2
weeks to be manifested fully. The efficacy of LTbR-Ig
treatment was routinely monitored with FACS analysis
to quantitate the reduction in the numbers of splenic
marginal-zone B cells (B220+, CD23low, CD21high,CD1high, data not shown). Parallel experiments were
conducted with TNFR-Ig to block TNF signaling.
TNFR-Ig was less effective than LTbR-Ig in reducing
the increase in LN cellularity (Figure 1B). In the nondrain-
ing axillary LN, TNF inhibition counteracted the small in-
crease in cellularity, but did not reduce cellularity below
the resting naive level.
LTbR-Ig Impairs Homing of Lymphocytes into
Lymph Nodes
To investigate whether the reduced cellularity in LN from
LTbR-Ig treated mice was due to decreased cell entry,
we examined short-term trafficking. Fluorescently la-
beled spleen cells were injected into control and LTbR-
Ig-treated mice. After 2–3 hr, the number of cells present
in the various LN was quantitated by FACS analysis. In
naive DBA-1, the number of B, CD4, or CD8 cells labeled
with CMFDA was reduced by LTbR-Ig treatment (Figure
2A). The same results were obtained if the data were ex-
pressed as a percentage of labeled cells (Figure 2B).
Similar data were obtained for both pLN and mesenteric
LN (mLN), whereas splenic entry was largely unaffected
(data not shown). Labeled-cell trafficking into PP from
DBA-1 mice was reduced by LTbR-Ig treatment (data
not shown). Analysis of trafficking into LN in Balb/c
mice also showed a similar pattern of impaired traffick-
ing (Figure 2C). The effects of LTbR-Ig on the T/B and
CD4/CD8 ratios were determined on both the resident
populations and the homing (CMFDA+) cells. A roughly
2-fold increase in the T/B ratio was consistently seen
in both populations in the pLN, but not in mLN, PP, or
spleen. The ratio of CD4 to CD8 cells in the short-term
homing experiments was also consistently increased
about 2-fold in all LN and PP but not in the spleen; how-
ever, this trend was less apparent at equilibrium. These
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more profoundly inhibited by LTbR-Ig relative to CD4
cell homing.
Figure 2. LTbR-Ig Treatment Results in Decreased Homing into LN
(A) Naive DBA-1 mice were treated with LTbR-Ig for 4 weeks, and the
trafficking of CMFDA-labeled total spleen cells into the LN was
quantitated. Panel (A) shows the numbers of CMFDA-labeled CD4,
CD8, or B cells that entered after 200 min into the cervical LN in con-
trol IgG (circles) or LTbR-Ig-treated (squares) mice. Data from two
separate trafficking experiments are pooled.
(B) Data from panel (A) are expressed as the percentage of cells (of
each subtype) that were CMFDA+ in the LN.
(C) Numbers of CMFDA+, CD4+ T cells that entered after 120 min into
various organs from Balb/c mice treated with control IgG or LTbR-Ig
for 4 weeks. Each symbol represents data from one mouse, p < 0.05
for each panel.In theory, inhibition of lymphocyte entry into LN
should increase the numbers of lymphocytes in the
spleen and peripheral blood. Indeed, both LTbR-Ig-trea-
ted mice and LT-deficient mice were found to have ele-
vated numbers of peripheral blood lymphocytes with
slightly increased granulocyte numbers (Figure 3). Lym-
phocytosis was noted previously in LTbR2/2 mice (Fut-
terer et al., 1998). Both LT-deficient and LTbR-Ig-treated
mice also exhibit a mild splenomegaly (Mackay et al.,
1997). The architecture of the spleen is disrupted in
LT-deficient mice, and given the size of this organ, one
could question whether the lymphocytosis stems from
this change. However, blood lymphocyte levels were
dramatically increased even when mice were splenec-
tomized first and then treated with LTbR-Ig (Figure 3).
Apparently, loss of a ‘‘buffering’’ capacity of the spleen
made the peripheral compartment more sensitive to
the loss of a LN entry mechanism. An anti-LTb blocking
mAb was active in this context, whereas TNFR-Ig treat-
ment was without effect (data not shown). These data
were consistent with the hypothesis that impaired entry
of lymphocytes into the LN led to more cells in the blood
and spleen.
Expression of PNAd and MAdCAM Is LT Dependent
Reduced trafficking of lymphocytes into the LN sug-
gested that addressin expression might be affected by
LTbR-Ig treatment. PNAd is recognized by the monoclo-
nal Ab MECA-79, which recognizes many, but not all, of
the glycans capable of binding to L-selectin (Ley, 2003;
van Zante et al., 2003). Both visual inspection and quan-
titative morphometric analyses revealed that the num-
bers of MECA-79-positive HEV decreased in LN from
LTbR-Ig-treated naive C57BL6 or Balb/c mice, although
some MECA-79-positive HEV remained (Figures 4A, 4D,
and 4E). To further evaluate the impact of LTbR-Ig treat-
ment on HEV status, we stained sections with L-selectin-
Ig to mark expression of all functional L-selectin ligands.
Overall, expression of L-selectin ligands detected in this
manner was also decreased in LN from LTbR-Ig-treated
mice (Figure 4B). Recent reports have suggested that the
luminal expression of PNAd may be regulated indepen-
dently from the abluminal expression (Drayton et al.,Figure 3. Loss of LTbR Signaling Leads to
Lymphocytosis
(A) Cell counts in the blood of Balb/c mice
treated for various times with LTbR-Ig (left
panels, n = 4), of LTa2/2 and LTb2/2 mice
(middle panels, n = 4), and of Balb/c mice
that were first splenectomized (SPx) or sham
operated and then treated with LTbR-Ig for 4
weeks (right panels, n = 3).
Means and SD are presented, and asterisks
indicate comparisons to control or wild-type
mice with p < 0.05.
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542Figure 4. The Loss of LTbR Signaling Decreases PNAd and MAdCAM Expression
(A) Reduced MECA-79 staining of HEV PNAd in axillary LN from LTbR-Ig-treated (d28) C57BL6 mice 4003 (insert 203).
(B) Staining of reactive DBA-1 draining iLN with L-selectin-Ig to reveal reduced L-selectin-ligand expression in LTbR-Ig-treated mice (2003, in-
sert 3003). Arrows indicate HEV-like vessels in LTbR-Ig-treated mice.
(C) Reduced staining of luminal MECA-79 on peripheral LN from LTbR-Ig-treated Balb/c mice. Mice were injected with MECA-79 30 min prior to
sacrifice to label the luminal face of the HEV (2003).
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and then MECA-79 was injected intravenously to label
the luminal surfaces of HEV. The MECA-79 that bound
to the luminal surfaces in vivo was subsequently de-
tected in tissue sections of harvested LN. LN from
LTbR-Ig-treated mice exhibited a profound reduction in
luminal PNAd epitopes (Figures 4C and 4F). This reduc-
tion was comparable to that observed when we used
L-selectin-Ig to mark total L-selectin-ligand expression,
indicating that LTbR-Ig treatment eliminates most L-se-
lectin ligands on HEV. The histological patterns pre-
sented here are consistent with the presence of some
LT-independent PNAd expression on HEV; whether this
MECA-79 staining was identical to the abluminal PNAd
described by others was not clear. LN staining by
a pan-endothelial marker, CD31/PECAM, was main-
tained even though MECA-79 staining was reduced by
LTbR-Ig (see the Supplemental Data available with this
article online). Consequently, the general vasculature is
not disrupted by loss of LTbR signaling, but rather the
HEV selectively loses aspects of its fully differentiated
status including most functional PNAd expression.
In the mucosal organs, i.e., mLN and PP, HEV express
primarily MAdCAM, but both L-selectin and integrin
a4b7 adhesion pathways are used by cells for entry
into mLN (Butcher et al., 1999). Staining of MAdCAM
with the monoclonal Ab MECA-367 was considerably re-
duced in the vasculature in mLN from LTbR-Ig-treated
animals (Figure 4G). Expression of PNAd in the mLN
was weak but was downmodulated further by LTbR-Ig
(Figure 4D). L-selectin-Ig binding was also substantially
reduced (Supplemental Data). Trafficking into Peyer’s
patches is dominated by integrin a4b7-MAdCAM inter-
actions, and MAdCAM-positive vessels were mostly ab-
sent in PP from LTbR-Ig-treated animals (Figure 4H).
LTbR-Ig Selectively Modulates Genes Associated
with Cell Trafficking in Resting Lymph Nodes
Quantitative PCR (Q-PCR) was used to assess the ex-
pression of a range of genes involved in cell trafficking
across the HEV in LN from naive C57BL6, Balb/c, and
DBA-1 mice and in multiple LN sets. GlcNAc6ST-2,
which is expressed uniquely by the HEV endothelium,
served as a direct marker for HEV status (Miyasaka
and Tanaka, 2004). LTbR-Ig treatment lowered the ex-
pression of GlcNAc6ST-2 about 10-fold in all LN exam-
ined (Figure 5A). Because the lymphocyte cell numbers
are decreased by LTbR-Ig treatment, the ratio of stromal
cell-RNA to lymphocyte-RNA may be artificially in-
creased, and hence the 10-fold reduction may be an un-
derestimate. As expected, splenic expression of this
gene was very low and not modulated by LTbR-Ig (Fig-
ure 5A). The results from an analysis of a panel of genes
relevant to LN trafficking are shown in Figure 5B. LikeGlcNAc6ST-2, GlcNAc6ST-1 expression was reduced,
whereas RNA levels of a third sulfotransferase, Gal6ST,
were not affected (data not shown). FucT VII levels de-
creased with treatment. FucT VII is expressed in leuco-
cytes and the vasculature, but expression in the LN ap-
pears to be dominated by LT-dependent sources, i.e.,
most likely the HEV. FucT IV is more widely expressed,
and RNA levels were only mildly reduced. Expression
of the scaffold proteins CD34 and GlyCAM was also
downmodulated, and GlyCAM expression in particular
was a very sensitive indicator of LTbR-Ig efficacy.
Several glycosylaminotransferases (GnT’s) were as-
sessed for LT-dependent expression. The glycosyl
transferases GnT1, GnT3, and GnT4 and the core 2 en-
zymes C2 GnT1, GnT2, and IGnT were not (<23) modu-
lated by LTbR-Ig treatment. E-selectin, P-selectin,
ICAM, and VCAM are involved in cell adhesion and traf-
ficking, but their expression was not modulated by treat-
ment (Figure 5B and not shown). The markers of estab-
lished and neovasculature, including CD31 (PECAM),
VE-cadherin, VEGFR-2, and integrin-b3, were not af-
fected, indicating that the LTbR-Ig treatment did not
lead to a generalized loss of vasculature. Major shifts
(i.e., >2-fold change) were not observed in a wide range
of other genes relevant to LN function, indicating that
the modulation of the subset of HEV-relevant genes
was highly specific (see Table S1).
LTbR-Ig treatment blocked MAdCAM expression in
pLN, mLN, and spleen (Figure 5B and data not shown).
In mLN, MAdCAM expression is markedly elevated
about 3–5-fold over that in pLN or spleen (data not
shown), and this difference most likely reflects the major
contribution by MAdCAM-positive HEV. Because this
‘‘increased’’ level of mLN MAdCAM RNA was substan-
tially reduced in LTbR-Ig-treated animals, mucosal
HEV MAdCAM expression must be reduced. This inter-
pretation was supported by the histological analyses
shown in Figure 4G. The reduced trafficking into mLN
appears to result from the loss of MAdCAM, which is
both the addressin for integrin a4b7 binding as well as
a scaffold for PNAd expression and decreased expres-
sion of the PNAd biosynthetic enzymes. In LN, MAdCAM
is also expressed by FDC networks in germinal centers,
and hence the reduction of RNA is not linked to exclu-
sively one cell type. However, MAdCAM expression was
not elevated in iLN from immunized DBA-1 mice that are
rich in germinal-center FDC networks, suggesting that
FDC do not contribute substantially to total MAdCAM
RNA levels in pLN. In the spleen, MAdCAM is expressed
in the endothelial lining of the marginal-zone sinus and in
secondary FDC networks, and neither structure remains
detectable in LTbR-Ig-treated animals, consistent with
the loss of splenic MAdCAM RNA expression. The che-
mokines CCL21 (SLC) and CXCL12 (SDF-1) and perhaps(D) Quantitation of the HEV staining in various LN from control-IgG-treated (blue) and LTbR-Ig-treated (red) naive C57BL6 mice. Data are ex-
pressed as the percentage of MECA-79-positive pixels in the total LN region. Values represent the mean and standard deviation (SD) from quan-
titation of at least five LN from different mice.
(E) Quantitation as per panel (D) of MECA-79+ HEV in LN from control-IgG- and LTbR-Ig-dosed naive Balb/c mice (day 28).
(F) Quantitation as per panel (D) of the luminal MECA-79 staining in panel (C) with LN from three different mice per treatment.
(G) Reduced MAdCAM staining (MECA 367) in mLN from naive C57B6 mice dosed with LTbR-Ig (2003, insert 3003). Morphometric quantitation
is shown alongside (n = 5 mice).
(H) Reduced MAdCAM staining in PP from naive C57BL6 mice (2003, insert 3003). Morphometric quantitation is shown alongside (multiple PP
from five separate mice).
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544Figure 5. Effects of LTbR-Ig Treatment on the
Expression of Various Genes Relevant to HEV
Trafficking
Q-PCR analysis of RNA from the entire LN is
shown following in vivo treatment for 28
days with either control IgG (blue), LTbR-Ig
(red), TNFR-Ig (green), or untreated (black).
(A) GlcNAc6ST-2 expression in various LN
from naive DBA-1 mice.
(B) Expression patterns of various genes in
axillary LN from naive Balb/c mice. LN from
4–5 mice were pooled, and mean and SD
from quadruplicate Q-PCR runs are plotted.
Relative RNA Q-PCR refers to the ratio of cy-
cle times for gene x to GAPDH, and the num-
ber under the gene designation indicates that
the actual ratio was scaled by the indicated
factor.CCL19 (ELC) are involved in the activation of rolling lym-
phocytes tethered to the HEV by L-selectin-PNAd bind-
ing. Modest modulation of CCL21 and CCL19 RNA levels
was observed in LTbR-Ig treated spleens (Ngo et al.,
1999), yet in LTbR-Ig-treated LN, we did not detect de-
creased CCL21 or CXCL12 RNA levels. Direct immuno-
histochemical analysis of CCL21 expression in pLN
from treated animals also did not reveal any changes
in the density of CCL21 staining around the HEV (Supple-
mental Data). Thus, CCL21 expression is not under LT
control in naive or reactive adult LN. CCL19 expression
was slightly decreased, less than 2-fold (Figure 5B).
CXCL13 (BLC) is critical for positioning of B cells and
a subset of T cells within the follicle (Cyster et al.,
2000). CXCL13 expression was downmodulated by
LTbR-Ig treatment in all settings, i.e., in spleen and in
resting and reactive LN. This result is consistent with
a substantial contribution by FDC networks, which are
ablated by LTbR signaling in all secondary lymphoid or-
gans (Cyster et al., 2000; Gommerman et al., 2002).
Surface LTa/b, and Not LIGHT or TNF, Is Required for
HEV Maintenance
LTbR-Ig binds to both LTa/b and LIGHT, and hence dis-
ruption of LIGHT binding to LTbR or to the alternate re-
ceptor, HVEM, could account for its activity. To deter-
mine whether LT or LIGHT was critical for HEV
maintenance, we examined LTb2/2 and TNF2/2 mice.
Because LTb2/2 mice lack pLN, we generated pLN,
i.e., cervical and axillary LN, in LTb2/2 mice by maternaladministration of an LTbR agonist mAb during gestation
to directly compare the HEV status of pLN with and with-
out LTb expression (Rennert et al., 1998). Q-PCR of RNA
from these LTbR agonist-induced pLN in LTb2/2 mice
revealed downmodulation of the same set of genes
that was reduced by LTbR-Ig treatment in LTb-replete
mice, i.e., CD34, GlyCAM, GlcNAc6ST-1, GlcNAc6ST-2,
and FucT VII (Figure 6A). About 50%–70% of our LTb2/2
mice also have a single atypically large mLN, perhaps re-
sulting from the funneling of all the lymphocytes draining
the small bowel into this single structure. Q-PCR of this
type of mLN from LTb2/2mice showed reduced expres-
sion of the same genes seen in the pLN and decreased
MAdCAM expression (Figure 6 and data not shown).
GlyCAM expression is very LT-dependent and, indeed,
RNA levels were even decreased in heterozygous
LTb+/2 mice. LTb+/2 mice have reduced surface LTa/b
levels, and heterozygosity had an impact on PP devel-
opment (Koni and Flavell, 1998; Koni et al., 1997).
Splenic expression of CD34 was also decreased in
LTb2/2 mice (data not shown). Analysis of TNF2/2 mice
showed that TNF was not involved in the regulation of
the addressin biosynthetic genes described here. One
possible exception may be GlcNAc6ST-1; however,
this gene was not appreciably downmodulated by
TNFR-Ig in wild-type mice. Consistent with prior obser-
vations in TNF2/2 mice showing the lack of FDC and
MAdCAM expression in the endothelial layer lining the
splenic marginal-zone sinus, MAdCAM RNA expression
was effectively absent in the spleens of TNF2/2 mice
Maintenance of HEV by LTbR Signaling
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critical for splenic marginal-zone and FDC networks,
and the very reduced MAdCAM RNA levels in spleens
from LTb2/2 and B cell-deficient mice was expected
(Fu and Chaplin, 1999). Because LT deficiency recapitu-
lated the downmodulation of the same set of genes as
LTbR-Ig, we conclude that LIGHT cannot substitute as
an LTbR ligand to maintain HEV status.
Figure 6. Loss of LT and Not TNF Signaling Leads to Collapse of the
HEV Maturation Program
(A) Q-PCR analysis of the expression of genes relevant critical to LN
HEV trafficking in various deficient mice. Data were obtained from
the aLN except as noted for MAdCAM expression in mLN and
spleen. In the case of LTb2/2mice, aLN were generated by maternal
transfer of anti-LTbR agonist mAb (n = 8). LN pools were obtained
from five mice in all other cases.
(B) A comparison of MECA-79 expression in the axillary LN from T
cell- (nu/nu) and B cell- (Jh) deficient mice showing that T and B
cell-deficient mice retain HEV. Hemotoxylin and eosin staining
(top) is shown for reference.
Means and SD in quadruplicate PCR runs are plotted.CXCL13 expression was essentially absent in both LN
and spleens from either TNF- or LT-deficient mice, as re-
ported earlier (Ngo et al., 1999). Yet in normal LN,
CXCL13 expression was downmodulated about 2–5-
fold by LTbR-Ig treatment, but not by TNFR-Ig. CCL21
expression paralleled that of CXCL13 in knockout ani-
mals, yet expression in LN from normal adult mice was
not appreciably affected by LTbR-Ig treatment (data
not shown and Figure 5B). These observations suggest
that there are late neonatal developmental events con-
tinuing in the LN that are LT dependent; however, once
development is completed, CCL21 is not under LT con-
trol. The set of genes associated with HEV addressins
was normally expressed in both B and T cell-deficient
mice. B and T cell-deficient mice (Jh and nu/nu) were ex-
amined for the presence of PNAd-positive HEV. LN from
these mice possessed bright MECA-79-positive HEV.
T cell-deficient mice had normal distributions of HEV,
whereas HEV in B cell-deficient mice were abnormally
clustered in a ring in the peripheral cortex next to the
subcapsular sinus (Figure 6B). Thus, both the histologi-
cal and gene-expression data indicate that the whole-
sale loss of T or B cells does not affect the HEV differen-
tiation program.
Modulation of HEV Status in Reactive Lymph Nodes
The loss of cellularity in reactive draining LN in CIA sug-
gested that in some settings, HEV in reactive LN were
under LT control. Gene-expression changes in reactive
LN were examined by Q-PCR at days 5–8 after immuni-
zation of C57BL6 mice with ovalbumin/CFA and in the
CIA setting. First, in reactive iLN from untreated
C57BL6 mice at day 5 or day 8 post-CFA/ovalbumin im-
munization, GlcNac6ST-2, GlyCAM, and CCL21 expres-
sion dropped substantially relative to naive LN, and
more-modest decreases occurred in GlcNac6ST-1 and
CD34 (Figure 7A and data not shown). At days 5 and 8
in LN from immunized C57BL6 mice, the levels of
GlcNAc6ST-2, GlyCAM, and CXCL13 were decreased
2–3-fold by LTbR-Ig treatment (Figure 7B and data not
shown). No substantial reductions were observed in
GlcNac6ST-1, FucT VII, CD34, GnT1, Gal6ST, and
CCL21 following LTbR-Ig treatment. TNFR-Ig treatment
had little effect on the expression of these genes. In the
CIA system, PNAd staining was reduced in draining iLN
from LTbR-Ig-treated animals at day 28 (Figure 7C). At
both day 28 and day 42, i.e., at 1 and 3 weeks after the
secondary boost, LTbR-Ig treatment led to a substantial
decrease in GlcNac6ST-1, GlcNAc6ST-2, GlyCAM,
CD34, FucTVII, and CXCL13 RNA in LN from LTbR-Ig-
treated animals (Figure 7D, and data not shown). These
observations show that the LT-dependence of HEV
maintenance in the resting state is also operative in
the reactive state in the settings described here.
Discussion
We have shown that a reduction in LN cellularity in adult
mice treated with LTbR-Ig correlated with decreased cell
entry rates and decreased display of the PNAd and
MAdCAM addressins. The loss of functional addressins
resulted from decreased expression of a diverse set of
genes encompassing multiple glycan biosynthetic en-
zymes essential for PNAd synthesis, PNAd scaffold
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(A) Time course of the expression of
GlcNAc6ST-2 and GlyCAM in draining (iLN)
and nondraining (cLN and mLN) nodes in
C57BL6 mice immunized in the tail on day
0 with CFA/ovalbumin.
(B) The effects of LTbR-Ig or TNFR-Ig treat-
ment from day 0 on GlcNAc6ST-2 and Gly-
CAM expression in the LN described in (A).
(C) Quantitation of the effect of LTbR-Ig treat-
ment on MECA-79 staining of draining iLN at
day 28 postimmunization of DBA-1 mice
with CFA/collagen II. Analysis was performed
as in Figure 4D (n = 5 mice).
(D) GlcNASc6ST-2 expression following vari-
ous treatments in draining (iLN), semidraining
(a/bLN), and nondraining (cLN) nodes from
collagen-immunized DBA-1 mice at day 28.
Colors indicate control Ig (blue), LTbR-Ig (red),
and TNFR-Ig (green). In (A) and (B), data are
the mean and SD of measurements on three
separate pools of LN with three mice contrib-
uting per pool.proteins, and also MAdCAM itself. The existence of such
a program of HEV differentiation was suggested by ear-
lier work where ligation of the afferent lymphatics rapidly
resulted in the loss of the ‘‘high’’ endothelial morphology
accompanied by decreased expression of the PNAd
scaffold protein GlyCAM and the enzyme FucT VII
and reduced anti-PNAd staining (Hendriks et al., 1987;
Mebius et al., 1993; Mebius et al., 1991; Swarte et al.,
1998). Some enzymes used to synthesize PNAd on en-
dothelium (e.g., fucosyl transferases) are also utilized
by lymphocytes to create ligands for E- and P-selectin.
Because mature lymphocytes do not express LTbR, as-
sembly of E- and P-selectin ligands on these cells is not
likely to be under LT control. In mucosal LN, trafficking
relies on both PNAd/MAdCAM:L-selectin and MAdCAM:
integrin-a4/b7 interactions (Butcher et al., 1999). The im-
paired trafficking into mLN of the LTbR-Ig-treated mice
reported here reflects a combined loss of PNAd and
MAdCAM addressins, consistent with the previously ob-
served flattening and decreased cellularity in PP from
LTbR-Ig-treated mice (Dohi et al., 2001).
Several previous studies suggested that the lympho-
toxin pathway was important in regulation of addressins
and HEV function. First, MAdCAM expression in the
splenic marginal-zone sinus was highly dependent on
continual LTbR signaling (Gommerman and Browning,
2003). Second, HEV in the mLN and NALT in LTb2/2
mice had only weak addressin expression, and also,
the pLN that form in LTa2/2 mice after maternal transfer
of a LTbR agonist mAb completely lacked PNAd-posi-
tive HEV (Rennert et al., 1997; Rennert et al., 1998;
Ying et al., 2005). Third, PNAd-positive HEV were found
in models of ectopic-lymphoid-tissue development in
the pancreas and kidneys of transgenic mice expressing
surface LTa/b (Drayton et al., 2003). MAdCAM- and
PNAd-positive HEV were found in the ectopic aggre-gates in the pancreas of RIP-CXCL13 transgenic mice,
and their formation required LTbR signaling (Luther
et al., 2000). Likewise, PNAd-positive HEV develop in ec-
topic lymphoid tissues in lungs of wild-type mice in-
fected with influenza virus, but not in virus-infected
LTa2/2 mice (Moyron-Quiroz et al., 2004). Work with de-
velopmentally induced ectopic lymphoid tissue in the
LTa/b transgenic mice led to the hypothesis that LT
may regulate GlcNAc6ST-2 expression (Drayton et al.,
2003). Fourth, LTbR inhibition decreased MAdCAM ex-
pression in the capillaries of the intestinal villi and re-
duced leukocyte rolling on inflamed capillaries in murine
colitis models (Mackay et al., 1998; Stopfer et al., 2004).
Likewise, LTbR-Ig treatment led to smaller MAdCAM-
positive HEV in colonic patches in mice with colitis
(Dohi et al., 2001). Lastly, genetic deletion of IKKa or
NFkB2, components of LTbR signaling, inhibited HEV
generation during development (Carragher et al., 2004;
Drayton et al., 2004). Such observations established an
initial link between LT signaling and development of
HEV either in lymph nodes or ectopic sites. Importantly,
here we demonstrate that in normal adult mice, contin-
ual LTbR activation controls a multigene expression pro-
file necessary to maintain addressin display and optimal
HEV function in pLN, mLN, and PP in both the resting
and reactive states.
LTbR signaling is critical for homeostatic maintenance
of follicular reticular networks, the splenic marginal
zone, and aspects of the intestinal immune system
(Gommerman and Browning, 2003; Wang and Fu,
2005; Ware, 2005). Unlike the paradigm in which cell-
surface LT on B cells maintains stromal reticular cells,
the HEV program in pLNs was not maintained solely by
either T or B cells and, moreover, SCID mice possess
HEV and HEV are retained 7 days after lymphocyte abla-
tion with irradiation (Duijvestijn et al., 1990; Sainte-Marie
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547and Peng, 1985). Therefore, the cellular source of LT
remains unclear, although there are other unusual LT-
positive cells such as the CD32, CD4+ cell described
by Lane and coworkers (Lane et al., 2005). LTa/b and
not LIGHT is the critical LTbR-ligand for HEV mainte-
nance because resting peripheral LN generated in LTb
deficient mice resemble LN from the LTbR-Ig-treated
mice. However, we cannot exclude a role for LIGHT in re-
active settings. Direct signaling to the HEV is possible
because endothelial cells in culture signal in response
to LTbR activation, and endothelial cells are LTbR posi-
tive (Drayton et al., 2004; Hochman et al., 1995) (and data
not shown). Despite the uncertainty at the cellular level,
the alternate NFkB pathway is likely involved. In this
pathway, activation of NFkB-inducing kinase (NIK) and
IKKa culminates in cleavage of NFkB2 and formation
of the active RelB/p50 complex (Bonizzi and Karin,
2004). NIK-deficient mice share many features of LTa/
b2 and LTbR-deficient mice. Likewise, NFkB22/2 and
IKKa2/2 mice have small LN and have been recently re-
ported to lack the HEV maturation program described
here (Carragher et al., 2004; Drayton et al., 2004). It is
reasonable to assume that LTbR couples to the induc-
tion of HEV differentiation via the alternate NFkB path-
way, although this signaling is often not wholly indepen-
dent of the classical pathway (Dejardin et al., 2002).
HEV status in response to mycobacterium adjuvant
was examined. LN expand following inflammatory stim-
uli frequently provided experimentally by toll-like recep-
tor activation with mycobacterial adjuvants. We found
that HEV status in reactive LN was LTbR dependent dur-
ing the first week following exposure to CFA/antigen in
C57BL6 mice as well as after secondary immunization
(day 21) in the draining LN in the DBA-1 CIA model. Sim-
ilarly, in the SJL/PLP relapsing EAE model, the cellularity
of the draining LN was decreased by LTbR-Ig treatment
(J.L.B. and J. Gommerman, unpublished data). In con-
trast, TNFR-Ig treatment affected neither the number
of HEV nor the gene-expression levels of key proteins
in either resting or reactive settings as was noted with
genetic deletion of TNF. TNFR-Ig blockade did reduce
cellularity somewhat in reactive LN in the CIA model;
however, LT pathway inhibition lowered cell numbers
below the resting state, e.g., aLN in Figure 1. Thus
whereas TNF production is a component of LN expan-
sion, the RNA expression data, leukocytosis, and PNAd
staining experiments do not support a direct role for TNF
in HEV maintenance. In mucosal settings, LTbR can reg-
ulate HEV status in the resting state and in reactive con-
ditions as inferred from the colitis studies (Mackay et al.,
1998; Stopfer et al., 2004). In experimental colitis, both
L-selectin and MAdCAM are required for T cell traffick-
ing into the inflamed gut (Rivera-Nieves et al., 2005).
In highly expanded draining LN of C57BL6 mice im-
munized with CFA/ovalbumin (20–40 3 106 cells per
LN), levels of GlcNAc6ST-2 and GlyCAM expression
were lower than in resting nodes. Previous studies
also showed that GlyCAM protein and RNA levels de-
creased in LN 3–8 days postimmunization, consistent
with the downmodulation in reactive LN of the HEV pro-
gram we describe (Hoke et al., 1995; Swarte et al., 1998).
Although decreased stromal RNA levels could be due to
increased lymphocyte-derived RNA in expanded nodes,
the simultaneous loss of HEV-addressin immuno-staining indicates a true downmodulation of PNAd sta-
tus. Likewise, we did not see parallel changes in genes
with primarily stromal expression patterns, e.g., LTbR,
CXCL13, and PECAM. An interesting possibility is that
in very expanded LN, the LT-positive cell that maintains
LTbR activation is diluted out. If so, HEV may become LT
independent when LN are highly expanded. In the CIA
system, LTbR-Ig reduced GlyCAM in the reactive, highly
expanded draining LN (10 3 106 cells/LN). Variability in
the exact size of reactive LN at day 28 (shortly after the
day 21 secondary boost) complicated matters some-
what. In experiments in which GlcNac6ST-2 RNA levels
were considerably reduced in the draining LN relative
to nondraining LN, we speculate that especially large
LN may underlie the results. In such cases, LTbR-Ig
treatment did not appreciably reduce GlcNac6ST-2
RNA (see example in Supplemental Data). Dilution of
the LT-positive driver cell could form a natural limitation
on LN size or at least the ratio of lymphocytes to HEV.
Similar arguments were made in the case of BAFF,
where B cell survival was affected by the total compart-
ment size and the net availability of BAFF (Lesley et al.,
2004).
This work shows that LTbR signaling controls an HEV-
differentiation subprogram that is dedicated to addres-
sin expression. The subprogram includes expression of
GlcNac6ST-1 and 2, GlyCAM, CD34, and FucT VII in the
resting LN. In reactive LN, the same gene set was down-
modulated in the DBA-1/CIA setting, and GlcNAc6ST-2
and GlyCAM expression were clearly decreased by days
5–8 in the draining LN in CFA/ovalbumin-immunized
C57BL6 mice. We think the ‘‘high’’ endothelial morphol-
ogy has collapsed (Supplemental Data), within the limits
of our methods to assess this aspect. Some aspects of
specialized HEV function are not under LT control, most
notably CCL21, but also potentially HEVIN and Cleaver
expression. Many of the LT-dependent genes described
here have been knocked out, and deficiency of L-selec-
tin, FucT VII, or combined GlcNAc6ST-1/GlcNAc6ST-2
or GlcNAc6ST-2/C2 GnT1 deficiencies cause a substan-
tial loss of HEV-dependent cell trafficking into the LN and
PP, similar to the effects of LTbR-Ig treatment (Hiraoka
et al., 2004; Homeister et al., 2001). Likewise, FucT VII2/2
mice exhibited peripheral lymphocytosis, and plt/plt
mice with a CCL19/21 defect also have increased T cell
numbers in the blood and mild splenomegaly, consistent
with the changes reported here (Homeister et al., 2001;
Nakano et al., 1997). The lymphocytosis in these various
deficient mice was generally milder than what we have
observed, suggesting that the mucosal compartment
may contribute substantially to this effect. Therefore,
the phenotype of the LTbR-Ig-treated mice was consis-
tent with broadly impaired PNAd and MAdCAM expres-
sion. Analysis of the single GlcNAc6ST-2 and C2 GnT1-
deficient mice showed that B cell trafficking across the
HEV was more sensitive to defects in PNAd assembly
when compared to T cells (Gauguet et al., 2004). Our T/
B ratio data also indicate a similar level of impaired B
cell trafficking into pLN following LTbR-Ig treatment. Cu-
riously, a defect in short-term CD8 trafficking was ob-
served in all LN groups, suggesting another unappreci-
ated component to their trafficking relative to CD4 cells.
Chronic inflammation leads to the formation of orga-
nized ectopic or tertiary lymphoid tissue capable of
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ferentiation of endothelium into HEV. These structures
are observed in a wide range of pathological settings in-
cluding autoimmune disease, infection, and heart-trans-
plant rejection (Bistrup et al., 2004; Weyand et al., 2001).
It is likely that LTbR signaling is a critical driving element
in some of these settings (Braun et al., 2004; Luther et al.,
2000). Not all ectopic sites exhibit this level of structure,
yet even in the absence of distinct B cell follicles, HEV
can be observed (van Dinther-Janssen et al., 1990; Yo-
neyama et al., 2001). It will be interesting to see whether
addressin expression is affected in nonendothelial sites,
e.g., MAdCAM on the inflamed choroid plexus in the brain
or perhaps the L-selectin ligands in CNS Myelin (Huang
et al., 1994; Wolburg et al., 1999). Ectopically expressed
addressins could facilitate entry of effector T cells, B
cells, and plasma cells into inflamed sites, and therefore
elimination of this entryportal maybe therapeuticallyuse-
ful. In primates, HEV status appears to be LT dependent
because lymphocytosis was observed in monkeys trea-
ted with LTbR-Ig (J.L.B., unpublished data and G. Koop-
man, personal communication).
Experimental Procedures
Mice
The following mice were purchased: DBA1/J, C57BL6, Balb/c, 129/
B6/TNF2/2, and C57BL6/scid mice (Jackson Labs); Jh and 129SvE
mice (Taconic); and athymic nude mice (Harlan). 129/B6 LTb2/2
were described previously (Koni et al., 1997). Female mice were stud-
ied at 8–12 weeks of age, except in Figure 2, where DBA-1 mice were
at 16 weeks. In the CIA model, male DBA-1 mice were used for most
experiments although trafficking changes were identical in female
DBA-1 mice (e.g., Figure 1B). Mice were immunized with collagen-
II/CFA or ovalbumin/CFA and boosted as described (Fava et al.,
2003). LNs were reconstituted in LTb2/2 mice by maternal transfer
of a LTbR agonist mAb AFH6 basically as described (Rennert et al.,
1998). LTbR-Ig, TNFR-Ig (both were murine receptor-human IgG1 fu-
sions), and human IgG control proteins have been described (Fava
et al., 2003). Mice were dosed once weekly by intraperitoneal injec-
tion with 100 mg protein; however, 200 mg TNFR-Ig was used in
some experiments to ensure effective coverage. All experimental
procedures were approved by the VA Institutional Review Board
and the Biogen Idec Institutional Animal Care and Use Committee.
Cell Isolation
Inguinal, mesenteric, cervical, axillary, and brachial LN were ob-
tained from groups of 3–6 animals for cell counts and FACS analy-
ses. Suspensions of LN or spleen cells were obtained by gently
mashing the organs between microscope slides, and cell counts
were obtained either manually or with a Beckman Coulter Vi-Cell
XR viable cell counter. Differential blood-cell counts were deter-
mined with the Abbott Diagnostics Cell Dyne Analyzer.
Quantitative PCR
Primer sets and methods are described in the Supplemental Data.
Cell Homing
Spleen cells from naive mice were labeled with 60 nM CMFDA (Green
tracker, Molecular Probes) for 10 min at RT and washed, and 23 107
total cells were injected intravenously into mice treated previously
for 4 weeks with control IgG or LTbR-Ig. Two to three hours later,
LN were harvested, and cells were stained for CD4, CD8a, and
B220 and analyzed by FACS.
Immunohistochemistry
Frozen or paraffin sections were stained for PNAd with MECA-79,
and frozen sections were stained for MAdCAM with MECA-367.
Bound Ab was detected with HRP-conjugated goat anti-rat IgM
(0.5 mg/ml) or HRP-conjugated goat anti-rat IgG (0.5 mg/ml), respec-tively, followed by Vector DAB and hematoxylin counterstain. For-
malin-fixed paraffin slides were stained with 2 mg/ml mouse L-selec-
tin-Ig (R&D Research) as described (Watson et al., 1990), except that
L-selectin-Ig was precomplexed to increase valency with protein A
in a 4:1 molar ratio (L-selectin-Ig:protein A). Bound Ig was detected
with HRP anti-human IgG. Quantitation of PNAd or MAdCAM was
performed by making digital images (from at least six different sec-
tions) of stained tissues from different mice, and the total area and
the area of positive staining were determined with NIH Image soft-
ware. For the detection of luminal PNAd, mice were injected intrave-
nously with 50 mg biotin-conjugated MECA-79 and sacrificed after
30 min.
Supplemental Data
Supplemental Data include one Supplemental Table, Supplemental
Experimental Procedures, and six Supplemental Figures and are
available with this article online at: http://www.immunity.com/cgi/
content/full/23/5/539/DC1/.
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